← Leaderboards
David Macpherson
Carnegie Institution Of Washington, D.C.
$15,229,761
Attributed
$16,592,537
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,592,537 · 11
By mechanism
R01$11,879,442 · 7
U01$2,687,366 · 1
P50$2,025,729 · 3
Top collaborators
- Robert Neil Eisenman6 shared
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsIn VivoGenesMutationTumorMouse ModelExhibitsTp53 GeneMutantLung Small Cell CarcinomaGenetic TranscriptionGeneticMolecularTranscriptome SequencingCell LineLeadNeurosecretory SystemsTumorigenesisMutateClustered Regularly Interspaced Short Palindromic RepeatsLungOverexpressionLinkTumor Suppressor Genes
Grant awards (40)
Interrogating roles for REST in small cell lung cancer therapy response and resistance$582,076
R01 · FY2025 · CA · contact PI
Interrogating a novel axis of tumor suppression in small cell lung cancer$548,915
R01 · FY2025 · CA · contact PI
Identifying and understanding drivers of chemoresistance in small cell lung cancer$545,661
R01 · FY2025 · CA · contact PI
Project 3: Targeting LSD1 to augment responses to PD-L1 inhibition in small cell lung cancer$308,965
P50 · FY2025 · CA · contact PI
Interrogating roles for REST in small cell lung cancer therapy response and resistance$582,076
R01 · FY2024 · CA · contact PI
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors$527,348
R01 · FY2024 · CA
Identifying and understanding drivers of chemoresistance in small cell lung cancer$503,547
R01 · FY2024 · CA · contact PI
Identifying and understanding drivers of chemoresistance in small cell lung cancer$545,661
R01 · FY2023 · CA · contact PI
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors$544,000
R01 · FY2023 · CA
Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC$506,274
U01 · FY2023 · CA · contact PI
Project 3: Identifying Determinants of Sensitivity to LSD1 Inhibition in SCLC$338,160
P50 · FY2023 · CA · contact PI
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors$544,000
R01 · FY2022 · CA
Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC$506,274
U01 · FY2022 · CA · contact PI
Project 3: Identifying Determinants of Sensitivity to LSD1 Inhibition in SCLC$338,160
P50 · FY2022 · CA · contact PI
Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC$516,606
U01 · FY2021 · CA · contact PI
Investigating CREBBP as a tumor suppressor in small cell lung cancer$441,962
R01 · FY2021 · CA · contact PI
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors$407,812
R01 · FY2021 · CA
Project 3: Identifying Determinants of Sensitivity to LSD1 Inhibition in SCLC$257,385
P50 · FY2021 · CA · contact PI
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors$147,290
R01 · FY2021 · CA
Project 3: Identifying Determinants of Sensitivity to LSD1 Inhibition in SCLC$80,605
P50 · FY2021 · CA · contact PI
Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC$641,606
U01 · FY2020 · CA · contact PI
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors$555,102
R01 · FY2020 · CA
Investigating CREBBP as a tumor suppressor in small cell lung cancer$441,962
R01 · FY2020 · CA · contact PI
Project 3: Identifying Determinants of Sensitivity to LSD1 Inhibition in SCLC$348,059
P50 · FY2020 · CA · contact PI
Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC$516,606
U01 · FY2019 · CA · contact PI
Investigating CREBBP as a tumor suppressor in small cell lung cancer$428,702
R01 · FY2019 · CA · contact PI
Interrogation of MLL2 as a tumor suppressor gene in lung cancer$390,521
R01 · FY2019 · CA · contact PI
Project 3: Identifying Determinants of Sensitivity to LSD1 Inhibition in SCLC$354,395
P50 · FY2019 · CA · contact PI
Investigating CREBBP as a tumor suppressor in small cell lung cancer$441,962
R01 · FY2018 · CA · contact PI
Interrogation of MLL2 as a tumor suppressor gene in lung cancer$402,600
R01 · FY2018 · CA · contact PI
Investigating CREBBP as a tumor suppressor in small cell lung cancer$441,962
R01 · FY2017 · CA · contact PI
Interrogation of MLL2 as a tumor suppressor gene in lung cancer$402,600
R01 · FY2017 · CA · contact PI
Interrogation of MLL2 as a tumor suppressor gene in lung cancer$402,600
R01 · FY2016 · CA · contact PI
Interrogation of MLL2 as a tumor suppressor gene in lung cancer$402,600
R01 · FY2015 · CA · contact PI
Using mouse models to understand retinoblastoma initiation and progression$386,570
R01 · FY2014 · CA · contact PI
Using mouse models to understand retinoblastoma initiation and progression$374,615
R01 · FY2013 · CA · contact PI
Using mouse models to understand retinoblastoma initiation and progression$205,248
R01 · FY2012 · CA · contact PI
Using mouse models to understand retinoblastoma initiation and progression$166,962
R01 · FY2012 · CA · contact PI
Using mouse models to understand retinoblastoma initiation and progression$353,238
R01 · FY2011 · CA · contact PI
Using mouse models to understand retinoblastoma initiation and progression$161,850
R01 · FY2010 · CA · contact PI